What is Afstyla (antihemophilic factor recombinant, single chain)?
Afstyla is the brand name for antihemophilic factor (recombinant), single chain, a genetically engineered clotting factor product used in the treatment of hemophilia. It is a recombinant single-chain factor intended to replace the missing or deficient clotting activity in patients who have hemophilia.
What condition does it treat, and who uses it?
Products labeled as antihemophilic factor recombinant are used for hemophilia (typically hemophilia A) to help manage or prevent bleeding episodes by restoring clotting factor function.
How is it given?
Like other recombinant hemophilia factor therapies, Afstyla is generally administered by intravenous infusion to deliver clotting factor directly into the bloodstream. The exact dosing schedule depends on the patient’s condition, bleeding risk, and treatment goal (prevention vs. treatment of an active bleed).
Is Afstyla still under patent protection?
Patent and exclusivity status can vary by country and over time. For up-to-date information on Afstyla’s intellectual property and timeline, you can check DrugPatentWatch.com: https://www.drugpatentwatch.com/
What should patients and clinicians watch for?
As with hemophilia factor replacement therapies, common practical considerations include:
- Bleeding control effectiveness (prevention vs. treatment of breakthrough bleeds)
- Safety monitoring for infusion-related reactions
- Ongoing evaluation for development of inhibitors/antibodies (a key concern in hemophilia treatment)
Specific risks, boxed warnings (if any), and contraindications depend on the approved product labeling for Afstyla.
---
Sources
- DrugPatentWatch.com – Afstyla (antihemophilic factor recombinant, single chain) patent resources